FDA Sends Warning Letters To Dietary Supplement Manufacturers Over Presence of Cesium Chloride

A number of dietary supplement manufacturers are illegally selling products containing cesium chloride, according to a warning issued by federal health regulators, who warn the products may pose serious safety risks for consumers.

The FDA issued a press release this week, announcing it has sent warning letters to American Nutriceuticals, LLC; Complete H2O Minerals, Inc; Daily Manufacturing, Inc.; Elemental Research, Inc.; The Mineral Store, Inc.; and Essence-of-Life, LLC, over the presence of cesium chloride in some of their dietary supplement products.

Cesium chloride is a mineral salt often promoted as an alternative treatment for cancer. However, no cesium chloride containing products have been approved by the FDA to treat cancer or any other disease. Cesium chloride is a new dietary ingredient that has not previously been present in the food supply in a non-chemically altered form. According to the FDA, it is subject to a 75-day premarket notification to establish its safety in dietary supplements.

Did You Know?

AT&T Data Breach Impacts Millions of Customers

More than 73 million customers of AT&T may have had their names, addresses, phone numbers, Social Security numbers and other information released on the dark web due to a massive AT&T data breach. Lawsuits are being pursued to obtain financial compensation.

Learn More

The companies selling the products must provide certain safety related information about the ingredient to the FDA before including it in a dietary supplement. However, companies marketing these products have not met this requirement and as a result their products cannot be legally marketed, the letters warn.

In February 2020, the FDA issued a public health alert warning consumers and healthcare providers to avoid using dietary supplements containing cesium salts, primarily cesium chloride.

Cesium chloride is associated with a lower blood level of potassium, which is a mineral that is essential to normal heart function. Using products containing cesium chloride may lead to heart problems.

“The FDA will continue to take action against dietary supplements that contain cesium chloride because of significant safety concerns—including heart toxicity and potential death—associated with this ingredient,” said Steven Tave, Director of the Office of Dietary Supplement Programs in the FDA’s Center for Food Safety and Applied Nutrition. “We take very seriously our role to protect the public from dangerous dietary supplements.”

The FDA requested a response from the companies within 15 working days to explain how they will correct the violations. Failure to correct the violations may result in legal action, including product seizure and or injunction.

Consumers who have experienced a reaction or illness related to using the product should contact their doctor and issue a complaint to the FDA’s MedWatch Adverse Event Reporting program.

0 Comments

Share Your Comments

I authorize the above comments be posted on this page*

Want your comments reviewed by a lawyer?

To have an attorney review your comments and contact you about a potential case, provide your contact information below. This will not be published.

NOTE: Providing information for review by an attorney does not form an attorney-client relationship.

This field is for validation purposes and should be left unchanged.

More Top Stories

BioZorb Lawsuit Alleges Breast Tissue Marker Failed, Requiring Surgical Removal
BioZorb Lawsuit Alleges Breast Tissue Marker Failed, Requiring Surgical Removal (Posted yesterday)

A BioZorb lawsuit has been filed by several breast cancer survivors after the BioZorb implants moved out of place and failed to dissolve int he body, requiring surgical removal.

Fairness Hearing For Philips CPAP Recall Medical Monitoring Settlement Set for October
Fairness Hearing For Philips CPAP Recall Medical Monitoring Settlement Set for October (Posted yesterday)

A U.S. District Court judge has scheduled a fairness hearing for October in order to determine whether final approval should be granted to a $25 million Philips CPAP recall settlement agreement, which would pay former users $25 million to pay for future medical monitoring needs.